Investigators > Jochen Prehn > Research, please also see Team Members and Mentoring and Supervision

Professor Prehns research interests include:

Total Publication: 212
Senior Author Publications: 93
Total Citations: >13,250
H Index (Google
Journal Articles: 182
Reviews: 19
Book Chapters: 12
Conference associated Publications: 216

Innovation/commercialisation activity
Licensed Technology: –
Name: Treatment of ALS and variants there of consisting of primary lateral sclerosis
(PLS) or Spinal Muscular Atrophy (SMA). Licensing Agreement Partner, August 16th,
2010: Athena Diagnositcs. Inc., (acquired in 2011 by Quest Diagnostics, Inc., from
Thermo Fisher Scientific) for diagnostic purposes (License).
Industry Collaborations:-
Pfizer, Global Biotherapeutics, Newgrange, Dublin, Ireland (SFI Biotherapeutics Award,
2014-2016); Pfizer, Groton, CT, USA (“Dimebon – Mechanisms of Action”, 2009-2010);
Luxcel Biosciences, Cork (Oxygen sensors; 2008-ongoing); Lundbeck A/S, Kopenhagen,
Denmark (“Neuroprotetctive properties of endogenous proteins and their modification”
2001 – 2003); Amgen Inc., Thousand Oaks, CA (“EPO-Derivatives and neuroprotection”;
2004); Siemens Research Ireland (“Computational analysis of signaling networks during
cell death”)

Measures of Esteem: 1993 Post-doctoral Fellowship Award, University of Chicago,
German Research Foundation (DFG);1998 Award of the Federal Ministry for Education
and Research (BMBF) for an Independent Research Group (DM 3.4M); 2003 Inaugural
Science Foundation Ireland Research Professor Award (€ 3.2M); 2009 Inaugural Royal
Irish Academy (RIA) Life Sciences Award. Invited Talks: 112 (Keystone, Gordon
Conferences, NIH and Max-Planck Society Symposia).
Professional Memberships: Director, MMI (2005-08); Founding Member, Irish Academy
of Medical Sciences (IAMS) (2011-).


Comments are closed.